psalexa
logo

Urinary Tract Infections (UTIs) Therapeutics - Pipeline Analysis 2018

Urinary Tract Infections (UTIs) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: February 2018
Report Code: LS11379
Available Format:
Pages: 145

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1.   Research Background

1.1   Research Objectives

1.2   Definition

1.3   Research Scope

1.3.1   Pipeline Analysis by Phase

1.3.2   Pipeline Analysis by Molecule Type

1.3.3   Pipeline Analysis by Route of Administration

1.4   Key Stakeholders

Chapter 2.   Research Methodology

2.1   Secondary Research

2.2   Primary Research

2.2.1   Breakdown of Primary Research Respondents

2.2.1.1   By industry participant

2.2.1.2   By company type

Chapter 3.   Executive Summary

Chapter 4.   Pipeline Outlook

4.1   Disease Overview

4.2   Sign & Symptoms

4.3   Epidemiology

4.4   Diagnosis

4.5   Prevention and Treatment

4.6   Key Drivers

4.6.1   Combination Therapies for Treating UTIs

4.6.2   Technological Advancements

4.7   Key Barriers

4.7.1   Risk Factors Involved in the Treatment of UTIs

4.8   UTIs Therapeutics Pipeline Analysis

4.8.1   Pipeline Analysis by Phase

4.8.2   Pipeline Analysis by Molecule Type

4.8.3   Pipeline Analysis by Route of Administration

4.8.4   Pipeline Analysis by Company

Chapter 5.   UTIs Therapeutics Pipeline Analysis by Phase (2018)

5.1   Filed

5.1.1   Plazomicin

5.1.1.1   Clinical trial

5.1.1.2   Results

5.1.1.3   Strategic development

5.2   Phase III (Expanded Access)

5.2.1   AB-PA01

5.2.1.1   Pre-Clinical studies

5.3   Phase III

5.3.1   MK-7655

5.3.1.1   Clinical trial

5.3.2   XXXX

5.3.2.1   Clinical trial

5.3.3   XXXX

5.3.3.1   Clinical trial

5.3.3.2   Clinical results

5.3.3.3   Strategic development

5.3.4   XXXX

5.3.4.1   Clinical trial

5.3.4.2   Strategic development

5.3.5   XXXX

5.3.5.1   Clinical trial

5.3.5.2   Strategic development

5.3.6   XXXX

5.3.6.1   Clinical trial

5.3.6.2   Clinical trial results

5.3.6.3   Strategic development

5.4   Phase II/III

5.4.1   LACTIN-V

5.4.1.1   Clinical trial

5.4.1.2   Clinical result

5.5   Phase II

5.5.1   XXXX

5.5.1.1   Clinical trials

5.5.1.2   Clinical results

5.5.1.3   Strategic development

5.5.2   XXXX

5.5.2.1   Clinical trials

5.5.2.2   Strategic development

5.5.3   XXXX

5.5.3.1   Clinical trials

5.5.3.2   Clinical trial results

5.5.3.3   Strategic development

5.5.4   XXXX

5.5.4.1   Clinical trials

5.5.5   XXXX

5.5.5.1   Pre-Clinical results

5.5.5.2   Clinical trials

5.5.5.3   Clinical trial results

5.5.5.4   Strategic development

5.6   Phase I

5.6.1   XXXX

5.6.2   XXXX

5.6.2.1   Strategic development

5.6.3   XXXX

5.6.3.1   Pre-Clinical studies

5.6.3.2   Clinical trials

5.6.3.3   Strategic development

5.6.3.4   Technology

5.6.4   XXXX

5.6.4.1   Clinical studies

5.6.4.2   Safety results

5.6.4.3   Pharmacokinetics results

5.6.4.4   Final Results

5.6.5   XXXX

5.6.6   XXXX

5.6.6.1   Clinical trials

5.6.6.2   Strategic development

5.6.6.3   Technology

5.6.7   XXXX

5.6.7.1   Clinical trials

5.6.7.2   Clinical results

5.6.7.3   Strategic development

5.6.8   XXXX

5.6.8.1   Clinical trials

5.6.8.2   Clinical trial results

5.6.8.3   Strategic development

5.6.9   XXXX

5.6.9.1   Clinical trials

5.6.9.2   Strategic development

5.7   IND

5.7.1   XXXX

5.7.1.1   Pre-Clinical studies

5.7.1.2   Strategic development

5.8   Pre-Clinical

5.8.1   XXXX

5.8.1.1   Pre-Clinical studies

5.8.2   XXXX

5.8.2.1   Pre-Clinical studies

5.8.3   XXXX

5.8.3.1   Strategic development

5.8.4   XXXX

5.8.5   XXXX

5.8.5.1   Pre-Clinical Results

5.8.6   XXXX

5.8.6.1   Strategic Development

5.8.7   XXXX

5.8.8   XXXX

5.8.8.1   Strategic development

5.8.9   XXXX

5.8.9.1   Strategic development

5.8.10   XXXX

5.9   Discovery

5.9.1   XXXX

5.9.2   XXXX

5.9.2.1   Technology

5.9.3   XXXX

5.9.4   XXXX

5.9.4.1   Strategic development

5.9.4.2   Technology

5.9.5   XXXX

5.1   Unknown

5.10.1   XXXX

5.10.1.1   Clinical trials

Chapter 6.   Clinical Trials Review

6.1   Clinical Trials by Region

6.2   Clinical Trials by Trial Status

Chapter 7.   Competitive Landscape

7.1   Key Players Benchmarking for UTIs Therapeutics Pipeline

7.2   SWOT Analysis of UTIs Therapeutics Pipeline

Chapter 8.   Company Profiles

8.1   Rebiotix Inc.

8.1.1   Business Overview

8.1.2   Products and Service Offerings

8.2   Company 2

8.2.1   Business Overview

8.2.2   Products and Service Offerings

8.3   Company 3

8.3.1   Business Overview

8.3.2   Products and Service Offerings

8.4   Company 4

8.4.1   Business Overview

8.4.2   Products and Service Offerings

8.5   Company 5

8.5.1   Business Overview

8.5.2   Products and Service Offerings

8.6   Company 6

8.6.1   Business Overview

8.6.2   Products and Service Offerings

8.7   Company 7

8.7.1   Business Overview

8.7.2   Product and Service Offerings

8.8   Company 8

8.8.1   Business Overview

8.8.2   Product and Service Offerings

8.9   Company 9

8.9.1   Business overview

8.9.2   Product and Service Offerings

8.10   Company 10

8.10.1   Business Overview

8.10.2   Product and Service Offerings

Chapter 9.   Appendix

9.1   Abbreviations

9.2   Related Reports

List of Tables  

  

TABLE 1      UTIs SYNDROMES: SIGNS, AND SYMPTOMS

TABLE 2      PIPELINE ANALYSIS OF UTIs THERAPEUTISCS, BY COMPANY (2018)

TABLE 3      DESCRIPTION OF PLAZOMICIN

TABLE 4      CLINICAL TRIALS OF PLAZOMICIN

TABLE 5      DETAILS OF PRIMARY END POINT 1

TABLE 6      DETAILS OF PRIMARY END POINT 2

TABLE 7      DESCRIPTION OF AB-PA01

TABLE 8      DESCRIPTION OF MK-7655

TABLE 9      CLINICAL TRIALS OF MK-7655

TABLE 10   DESCRIPTION OF XXXX

TABLE 11   CLINICAL TRIALS OF XXXX

TABLE 12   DESCRIPTION OF XXXX

TABLE 13   CLINICAL TRIALS OF XXXX

TABLE 14   DESCRIPTION OF XXXX

TABLE 15   DESCRIPTION OF XXXX

TABLE 16   CLINICAL TRIALS OF XXXX

TABLE 17   DESCRIPTION OF XXXX

TABLE 18   CLINICAL TRIALS OF XXXX

TABLE 19   DESCRIPTION OF LACTIN-V

TABLE 20   CLINICAL TRIALS OF LACTIN-V

TABLE 21   DESCRIPTION OF XXXX

TABLE 22   CLINICAL TRIALS OF XXXX

TABLE 23   DESCRIPTION OF XXXX

TABLE 24   CLINICAL TRIALS OF XXXX

TABLE 25   DESCRIPTION OF XXXX

TABLE 26   CLINICAL TRIALS OF XXXX

TABLE 27   DETAILS OF ENDPOINT 1

TABLE 28   DETAILS OF ENDPOINT 2

TABLE 29   DETAILS OF ENDPOINT 3

TABLE 30   DESCRIPTION OF XXXX

TABLE 31   CLINICAL TRIALS OF XXXX

TABLE 32   DESCRIPTION OF XXXX

TABLE 33   DESCRIPTION OF XXXX

TABLE 34   DESCRIPTION OF XXXX

TABLE 35   DESCRIPTION OF XXXX

TABLE 36   DESCRIPTION OF XXXX

TABLE 37   DESCRIPTION OF XXXX

TABLE 38   DESCRIPTION OF XXXX

TABLE 39   CLINICAL TRIALS OF XXXX

TABLE 40   DESCRIPTION OF XXXX

TABLE 41   CLINICAL TRIALS OF XXXX

TABLE 42   DESCRIPTION OF XXXX

TABLE 43   CLINICAL TRIALS OF XXXX

TABLE 44   DESCRIPTION OF XXXX

TABLE 45   CLINICAL TRIALS OF XXXX

TABLE 46   DESCRIPTION OF XXXX

TABLE 47   DESCRIPTION OF XXXX

TABLE 48   DESCRIPTION OF XXXX

TABLE 49   DESCRIPTION OF XXXX

TABLE 50   DESCRIPTION OF XXXX

TABLE 51   DESCRIPTION OF XXXX

TABLE 52   DESCRIPTION OF XXXX

TABLE 53   DESCRIPTION OF XXXX

TABLE 54   DESCRIPTION OF XXXX

TABLE 55   DESCRIPTION OF XXXX

TABLE 56   DESCRIPTION OF XXXX

TABLE 57   DESCRIPTION OF XXXX

TABLE 58   DESCRIPTION OF XXXX

TABLE 59   DESCRIPTION OF XXXX

TABLE 60   DESCRIPTION OF XXXX

TABLE 61   DESCRIPTION OF XXXX

TABLE 62   DESCRIPTION OF XXXX

TABLE 63   CLINICAL TRIALS OF XXXX

TABLE 64   REBIOTIX INC. - AT A GLANCE

TABLE 65   COMPANY 2 - AT A GLANCE

TABLE 66   COMPANY 3 - AT A GLANCE

TABLE 67   COMPANY 4 - AT A GLANCE

TABLE 68   COMPANY 5 - AT A GLANCE

TABLE 69   COMPANY 6 - AT A GLANCE

TABLE 70   COMPANY 7 - AT A GLANCE

TABLE 71   COMPANY 8 - AT A GLANCE

TABLE 72   COMPANY 9 - AT A GLANCE

TABLE 73   COMPANY 10 - AT A GLANCE

  

List of Figures  

  

FIG 1:   RESEARCH METHODOLOGY

FIG 2:   BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3:   BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4:   UTIs DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 5:   UTIs PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6:   UTIs PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7:   BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8:   BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

 

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry